Gilead pushes into inflammation and oncology as it seeks to diversify beyond HIV franchise

Gilead reported that HIV remained its strongest franchise in the second quarter, but the company is actively building a pipeline outside virology.

CEO Daniel O’Day told investors that diversification is a core objective, while a Citi analyst noted that sales from non‑HIV areas have not yet materialized.

The chief medical officer highlighted several upcoming readouts that could broaden the commercial portfolio, including a Phase 2 SWIFT trial of the integrin inhibitor emvistegrast for ulcer‑related disease.

These catalysts are expected in the back half of 2026 and are seen as key to reducing the company’s reliance on HIV revenue.